These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

162 related items for PubMed ID: 21127445

  • 1. The impact of FDG-PET/CT on the management of breast cancer patients with elevated tumor markers and negative or equivocal conventional imaging modalities.
    Filippi V, Malamitsi J, Vlachou F, Laspas F, Georgiou E, Prassopoulos V, Andreou J.
    Nucl Med Commun; 2011 Feb; 32(2):85-90. PubMed ID: 21127445
    [Abstract] [Full Text] [Related]

  • 2. ¹⁸F-Fluorodeoxyglucose positron emission tomography/computed tomography finds answers in cancer patients with increasing tumor markers and negative or equivocal conventional imaging modalities.
    Salem SS, Shahin MA.
    Nucl Med Commun; 2012 Mar; 33(3):313-21. PubMed ID: 22237387
    [Abstract] [Full Text] [Related]

  • 3. Clinical utility of F-18 FDG PET/CT in recurrent breast carcinoma.
    Manohar K, Mittal BR, Senthil R, Kashyap R, Bhattacharya A, Singh G.
    Nucl Med Commun; 2012 Jun; 33(6):591-6. PubMed ID: 22334135
    [Abstract] [Full Text] [Related]

  • 4. Early diagnosis of recurrent breast cancer with FDG-PET in patients with progressive elevation of serum tumor markers.
    Suárez M, Pérez-Castejón MJ, Jiménez A, Domper M, Ruiz G, Montz R, Carreras JL.
    Q J Nucl Med; 2002 Jun; 46(2):113-21. PubMed ID: 12114874
    [Abstract] [Full Text] [Related]

  • 5. High incidence of peritoneal implants in recurrence of intra-abdominal cancer revealed by 18F-FDG PET/CT in patients with increased tumor markers and negative findings on conventional imaging.
    Panagiotidis E, Datseris IE, Exarhos D, Skilakaki M, Skoura E, Bamias A.
    Nucl Med Commun; 2012 Apr; 33(4):431-8. PubMed ID: 22293498
    [Abstract] [Full Text] [Related]

  • 6. Clinical value of F18-fluorodeoxyglucose positron emission tomography-computed tomography in patients with non-small cell lung cancer after potentially curative surgery: experience with 241 patients.
    Kanzaki R, Higashiyama M, Maeda J, Okami J, Hosoki T, Hasegawa Y, Takami M, Kodama K.
    Interact Cardiovasc Thorac Surg; 2010 Jun; 10(6):1009-14. PubMed ID: 20197344
    [Abstract] [Full Text] [Related]

  • 7. [Diagnostic and therapeutic impact of 18F-FDG-PET/CT in patients with suspected breast cancer recurrence].
    Palomar Muñoz A, García Vicente AM, Talavera Rubio MP, Pilkington Woll JP, Poblete García VM, Bellón Guardia ME, León Martín A, Cordero García JM, Soriano Castrejón A.
    Rev Esp Med Nucl; 2010 Jun; 29(3):100-8. PubMed ID: 20392542
    [Abstract] [Full Text] [Related]

  • 8. Breast cancer recurrence diagnosis suspected on tumor marker rising: value of whole-body 18FDG-PET/CT imaging and impact on patient management.
    Champion L, Brain E, Giraudet AL, Le Stanc E, Wartski M, Edeline V, Madar O, Bellet D, Pecking A, Alberini JL.
    Cancer; 2011 Apr 15; 117(8):1621-9. PubMed ID: 21472709
    [Abstract] [Full Text] [Related]

  • 9. F-18 fluorodeoxyglucose positron-emission tomography in the diagnosis of tumor recurrence and metastases in the follow-up of patients with breast carcinoma: a comparison to conventional imaging.
    Gallowitsch HJ, Kresnik E, Gasser J, Kumnig G, Igerc I, Mikosch P, Lind P.
    Invest Radiol; 2003 May 15; 38(5):250-6. PubMed ID: 12750613
    [Abstract] [Full Text] [Related]

  • 10. Role of 2-[18F] fluoro-2-deoxy-D-glucose-positron emission tomography/computed tomography in the post-therapy surveillance of breast cancer.
    Chang HT, Hu C, Chiu YL, Peng NJ, Liu RS.
    PLoS One; 2014 May 15; 9(12):e115127. PubMed ID: 25517451
    [Abstract] [Full Text] [Related]

  • 11. 18F-FDG-PET/CT in patients with breast cancer and rising Ca 15-3 with negative conventional imaging: a multicentre study.
    Grassetto G, Fornasiero A, Otello D, Bonciarelli G, Rossi E, Nashimben O, Minicozzi AM, Crepaldi G, Pasini F, Facci E, Mandoliti G, Marzola MC, Al-Nahhas A, Rubello D.
    Eur J Radiol; 2011 Dec 15; 80(3):828-33. PubMed ID: 20547020
    [Abstract] [Full Text] [Related]

  • 12. The role of FDG PET/CT in patients with locoregional breast cancer recurrence: a comparison to conventional imaging techniques.
    Aukema TS, Rutgers EJ, Vogel WV, Teertstra HJ, Oldenburg HS, Vrancken Peeters MT, Wesseling J, Russell NS, Valdés Olmos RA.
    Eur J Surg Oncol; 2010 Apr 15; 36(4):387-92. PubMed ID: 19962268
    [Abstract] [Full Text] [Related]

  • 13. Role of FDG PET-CT in asymptomatic epithelial ovarian cancer with rising serum CA-125: a pilot study.
    Ghosh J, Thulkar S, Kumar R, Malhotra A, Kumar A, Kumar L.
    Natl Med J India; 2013 Apr 15; 26(6):327-31. PubMed ID: 25073988
    [Abstract] [Full Text] [Related]

  • 14. [The role of 18F-FDG SPECT-CT in detecting recurrence and metastases in breast cancer patients with elevated tumor markers].
    Xing Y, Zhao JH, Wang TS, Qiao WL, Che WJ.
    Zhonghua Zhong Liu Za Zhi; 2009 Feb 15; 31(2):129-33. PubMed ID: 19538891
    [Abstract] [Full Text] [Related]

  • 15. Combined [18F]Fluorodeoxyglucose positron emission tomography and computed tomography (FDG-PET/CT) for detection of recurrent, 131I-negative thyroid cancer.
    Finkelstein SE, Grigsby PW, Siegel BA, Dehdashti F, Moley JF, Hall BL.
    Ann Surg Oncol; 2008 Jan 15; 15(1):286-92. PubMed ID: 17882493
    [Abstract] [Full Text] [Related]

  • 16. Impact of PET/CT in comparison with same day contrast enhanced CT in breast cancer management.
    Piperkova E, Raphael B, Altinyay ME, Castellon I, Libes R, Sandella N, Heiba S, Abdel-Dayem H.
    Clin Nucl Med; 2007 Jun 15; 32(6):429-34. PubMed ID: 17515747
    [Abstract] [Full Text] [Related]

  • 17. 18F-FDG PET/CT as a staging procedure in primary stage II and III breast cancer: comparison with conventional imaging techniques.
    Koolen BB, Vrancken Peeters MJ, Aukema TS, Vogel WV, Oldenburg HS, van der Hage JA, Hoefnagel CA, Stokkel MP, Loo CE, Rodenhuis S, Rutgers EJ, Valdés Olmos RA.
    Breast Cancer Res Treat; 2012 Jan 15; 131(1):117-26. PubMed ID: 21935602
    [Abstract] [Full Text] [Related]

  • 18. Value of FDG PET imaging in the management of patients with thyroid, neuroendocrine, and neural crest tumors.
    Scanga DR, Martin WH, Delbeke D.
    Clin Nucl Med; 2004 Feb 15; 29(2):86-90. PubMed ID: 14734903
    [Abstract] [Full Text] [Related]

  • 19. The role of FDG-PET/CT in suspected recurrence of breast cancer.
    Radan L, Ben-Haim S, Bar-Shalom R, Guralnik L, Israel O.
    Cancer; 2006 Dec 01; 107(11):2545-51. PubMed ID: 17063499
    [Abstract] [Full Text] [Related]

  • 20. Role of [(18)F]FDG-PET/CT in the detection of occult recurrent medullary thyroid cancer.
    Skoura E, Rondogianni P, Alevizaki M, Tzanela M, Tsagarakis S, Piaditis G, Tolis G, Datseris IE.
    Nucl Med Commun; 2010 Jun 01; 31(6):567-75. PubMed ID: 20335822
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.